Based on the results of the bioinformatics analysis and IHC, we determined that FAM57A could potentially serve as a biomarker to predict the prognosis of and immunotherapy response to HCC, and it might function as an oncogene in the progression of HCC. Here, TLCD3A is linked to hepatocellular carcinoma.